ALA-HIST PE- phenylephrine hydrochloride, dexbrompheniramine maleate tablet
Poly Pharmaceuticals, Inc.
Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
----------
Active ingredients
(in each tablet)
Dexbrompheniramine Maleate 2 mg
Phenylephrine Hydrochloride 10 mg
Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies:
Do not exceed recommended dosage.
Adults and children 12
years of age and over: | 1 tablet every 4 to 6
hours, not to exceed 6 tablets in 24 hours |
Children 6 to under 12
years of age: | 1/2 tablet every 4 to
6 hours, not to exceed 3 tablets in 24 hours |
Children under 6 years
of age: | Consult a doctor
|
Store at 15° - 30°C (59° - 86°F). Supplied in a tight, light-resistant container with a child-resistant cap. Ala-Hist PE Tablets are dark purple, caplet-shaped, scored tablets, debossed "Poly" bisect "782" on one side and plain on the other.
colloidal silicon dioxide, croscarmellose sodium, D&C Red #27 aluminum lake, dibasic calcium phosphate dihydrate, FD &C Blue #1 aluminum lake, magnesium stearate, and silicified microcrystalline cellulose.
The packaging below represents the labeling currently used.
Principal display panel and side panel for 90 tablets label:
NDC 50991-782-90
ALA-HIST PE
Tablets
Antihistamine • Nasal Decongestant
Each tablet contains:
Dexbrompheniramine Maleate......................2 mg
Phenylephrine Hydrochloride......................10 mg
90 Tablets
Usual Dosage: See product foldout for full prescribing information.
Tamper evident by foil seal under cap. Do not use if foil seal isbroken or missing.
KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.
Store at controlled room temperature between 15°-30°C (59°-86°F).
Manufactured for:
Poly Pharmaceuticals
Rev. 06/19
ALA-HIST PE
phenylephrine hydrochloride, dexbrompheniramine maleate tablet |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
|
Labeler - Poly Pharmaceuticals, Inc. (198449894) |